Teva Canada has launched the Aermony RespiClick fluticasone propionate DPI for the treatment of asthma, the company said. The inhaler will be available in 55 mcg, 113 mcg, and 232 mcg per actuation versions.
According to the Health Canada web site, Aermony Respiclick was approved in 2017, the same year that ArmonAir Resplick fluticasone propionate was approved in the US. A February 2020 British Columbia Ministry of Health document says that “Teva Canada Innovation confirmed that they are unable to bring Aermony Respiclick to the Canadian market at sufficient quantities at this time. “The Canadian launch of Aermony Respiclick comes two weeks after Teva launched ArmonAir Digihaler and AirDuo Digihaler in the US.
A Canadian version of AirDuo Respiclick, Arbesda Respiclick fluticasone propionate / salmeterol, was approved in December 2018; the British Columbia Ministry of Health also noted in February 2020 that Teva Canada said that it could not provide sufficient quantities of that DPI to the Canadian market.
Teva Canada General Manager Christine Poulin commented, “We’re pleased that Aermony RespiClick is now available in Canada. With this innovative method of delivery of medication, respirologists and asthma patients will experience the simplified administration features the RespiClick device has to offer Aermony RespiClick is a meaningful expansion of our offerings in respirology, which currently include both proprietary and generic products.”
Read the Teva Canada press release.
